SREBF1 and metabolic dysfunction-associated steatotic liver disease: In human studies, increases in MUFA, PUFA and n-3 PUFA have been shown to reduce hepatic lipid content and improve metabolic control in NAFLD patients [73,100], potentially due to increase fatty acid oxidation, redistribution of fatty acids and down regulation of gene expression of sterol regulatory element binding protein 1 (SREBP1-c) and factor for apoptosis (FAS).